Yifeng Pharmacy Chain Co., Ltd. (SHA:603939)
China · Delayed Price · Currency is CNY 25.19
-0.18 (-0.71%)
At close: Feb 6, 2026
Yifeng Pharmacy Chain Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 23,362 | 23,295 | 22,078 | 19,382 | 14,807 | 12,813 |
Other Revenue | 767.13 | 767.13 | 510.66 | 504.62 | 519 | 331.15 |
| 24,129 | 24,062 | 22,588 | 19,886 | 15,326 | 13,145 | |
Revenue Growth (YoY) | 0.88% | 6.53% | 13.59% | 29.75% | 16.60% | 27.91% |
Cost of Revenue | 14,530 | 14,492 | 14,030 | 12,082 | 9,184 | 8,183 |
Gross Profit | 9,600 | 9,570 | 8,558 | 7,805 | 6,143 | 4,961 |
Selling, General & Admin | 7,155 | 7,262 | 6,450 | 5,782 | 4,717 | 3,705 |
Research & Development | 30.26 | 33.94 | 33.55 | 25.31 | 15.64 | 8.31 |
Other Operating Expenses | 42.52 | 52.63 | 57.59 | 59.1 | 28.18 | 49.95 |
Operating Expenses | 7,221 | 7,347 | 6,546 | 5,877 | 4,765 | 3,770 |
Operating Income | 2,378 | 2,224 | 2,012 | 1,928 | 1,377 | 1,191 |
Interest Expense | -204.38 | -221.37 | -160.53 | -165.21 | -168.99 | -186.08 |
Interest & Investment Income | 195.1 | 180.78 | 135.66 | 80.08 | 98.51 | 87.92 |
Other Non Operating Income (Expenses) | -35.42 | -25.18 | -18.94 | -12.81 | -10.03 | -13.94 |
EBT Excluding Unusual Items | 2,334 | 2,158 | 1,969 | 1,830 | 1,297 | 1,079 |
Impairment of Goodwill | -18.83 | -18.83 | - | - | - | - |
Gain (Loss) on Sale of Assets | 75.96 | 49.94 | 41.82 | 23.17 | 6.85 | 0.32 |
Asset Writedown | -15.73 | -3.84 | -12.73 | -10.33 | -1.43 | -1.58 |
Other Unusual Items | -2.66 | -2.66 | 39.87 | 34.99 | 35.49 | 49.39 |
Pretax Income | 2,372 | 2,182 | 2,038 | 1,877 | 1,338 | 1,127 |
Income Tax Expense | 596.88 | 529.67 | 456.66 | 454.06 | 347.16 | 287.92 |
Earnings From Continuing Operations | 1,776 | 1,653 | 1,581 | 1,423 | 990.75 | 839.44 |
Minority Interest in Earnings | -132.9 | -124.21 | -168.95 | -161.58 | -102.86 | -95.92 |
Net Income | 1,643 | 1,529 | 1,412 | 1,262 | 887.88 | 743.52 |
Net Income to Common | 1,643 | 1,529 | 1,412 | 1,262 | 887.88 | 743.52 |
Net Income Growth | 7.83% | 8.26% | 11.90% | 42.12% | 19.42% | 36.74% |
Shares Outstanding (Basic) | 1,217 | 1,213 | 1,207 | 1,202 | 1,193 | 1,157 |
Shares Outstanding (Diluted) | 1,255 | 1,233 | 1,207 | 1,211 | 1,203 | 1,157 |
Shares Change (YoY) | 3.79% | 2.15% | -0.37% | 0.70% | 4.01% | 0.31% |
EPS (Basic) | 1.35 | 1.26 | 1.17 | 1.05 | 0.74 | 0.64 |
EPS (Diluted) | 1.31 | 1.24 | 1.17 | 1.04 | 0.74 | 0.64 |
EPS Growth | 3.89% | 5.98% | 12.32% | 41.13% | 14.81% | 36.32% |
Free Cash Flow | 2,676 | 3,539 | 3,884 | 3,333 | 1,322 | 1,747 |
Free Cash Flow Per Share | 2.13 | 2.87 | 3.22 | 2.75 | 1.10 | 1.51 |
Dividend Per Share | 0.700 | 0.650 | 0.417 | 0.238 | 0.179 | 0.137 |
Dividend Growth | 5.00% | 55.99% | 75.01% | 33.31% | 29.98% | - |
Gross Margin | 39.78% | 39.77% | 37.89% | 39.25% | 40.08% | 37.74% |
Operating Margin | 9.86% | 9.24% | 8.91% | 9.69% | 8.99% | 9.06% |
Profit Margin | 6.81% | 6.35% | 6.25% | 6.35% | 5.79% | 5.66% |
Free Cash Flow Margin | 11.09% | 14.71% | 17.19% | 16.76% | 8.63% | 13.29% |
EBITDA | 2,651 | 2,473 | 2,231 | 2,115 | 1,521 | 1,303 |
EBITDA Margin | 10.99% | 10.28% | 9.88% | 10.63% | 9.93% | 9.91% |
D&A For EBITDA | 272.51 | 249.36 | 218.51 | 186.98 | 143.94 | 111.4 |
EBIT | 2,378 | 2,224 | 2,012 | 1,928 | 1,377 | 1,191 |
EBIT Margin | 9.86% | 9.24% | 8.91% | 9.69% | 8.99% | 9.06% |
Effective Tax Rate | 25.16% | 24.27% | 22.41% | 24.19% | 25.95% | 25.54% |
Revenue as Reported | 24,129 | 24,062 | 22,588 | 19,886 | 15,326 | 13,145 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.